| Dec'19 | Dec'18 | Dec'17 | ||||
|---|---|---|---|---|---|---|
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||
NET LOSS ATTRIBUTABLE TO AGEX | ||||||
-12,154 | -7,502 | -6,580 | ||||
Net loss attributable to noncontrolling interest | ||||||
-230 | -229 | -57 | ||||
Adjustments to reconcile net loss attributable to AgeX to net cash used in operating activities: | ||||||
Gain on sale of equity method investment in Ascendance | ||||||
354 | 3,215 | - | ||||
Acquired in-process research and development | ||||||
- | 800 | - | ||||
Depreciation expense | ||||||
91 | 58 | 165 | ||||
Amortization of intangible assets | ||||||
558 | 477 | 517 | ||||
Amortization of right-of-use asset | ||||||
302 | - | - | ||||
Amortization of debt issuance cost | ||||||
54 | - | - | ||||
Amortization of deferred license fees | ||||||
- | - | 17 | ||||
Gain on sale of assets | ||||||
- | - | 1,754 | ||||
Stock-based compensation | ||||||
1,907 | 1,285 | 114 | ||||
Stock-based compensation allocated from Lineage | ||||||
- | 184 | 411 | ||||
Subsidiary stock-based compensation | ||||||
- | 4 | 227 | ||||
Bad debt expense | ||||||
- | - | -121 | ||||
Foreign currency remeasurement gain (loss) and other | ||||||
-76 | 68 | - | ||||
Changes in operating assets and liabilities: | ||||||
Accounts and grants receivable, net | ||||||
232 | 24 | -322 | ||||
Prepaid expenses and other current assets | ||||||
-473 | 219 | -10 | ||||
Accounts payable and accrued liabilities | ||||||
169 | 648 | 267 | ||||
Related party payables | ||||||
-68 | -128 | - | ||||
Insurance premium liability | ||||||
-599 | -74 | - | ||||
Deferred revenues | ||||||
-34 | 137 | -84 | ||||
Other current liabilities | ||||||
-119 | -129 | - | ||||
Other current liabilities | ||||||
- | - | 261 | ||||
Net cash used in operating activities | ||||||
-10,160 | -7,995 | -6,285 | ||||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||
Proceeds from the sale of equity method investment in Ascendance | ||||||
354 | 3,215 | - | ||||
Purchase of in-process research and development | ||||||
- | 1,872 | - | ||||
Security deposit (paid) received and other, net | ||||||
74 | -5 | - | ||||
Purchase of equipment and other | ||||||
641 | 21 | 1 | ||||
Removal of cash upon deconsolidation of LifeMap Solutions | ||||||
- | - | 3 | ||||
Security deposit received and other, net | ||||||
- | - | 9 | ||||
Net cash used in investing activities | ||||||
-361 | 1,327 | 5 | ||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||
Contributions from BioTime | ||||||
- | - | 1,971 | ||||
Advances from BioTime | ||||||
- | - | 1,304 | ||||
Proceeds from issuance of common stock | ||||||
- | 5,000 | 10,000 | ||||
Proceeds from sale of warrants | ||||||
- | 1,000 | - | ||||
Proceeds from exercise of warrants | ||||||
4,500 | - | - | ||||
Draw down on loan facility from Juvenescence | ||||||
1,800 | - | - | ||||
Repayment of financing lease liability | ||||||
35 | - | - | ||||
Net cash provided by financing activities | ||||||
6,265 | 6,000 | 13,275 | ||||
Effect of exchange rate changes on cash and cash equivalents | ||||||
1 | - | - | ||||
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | ||||||
-4,255 | -668 | - | ||||
Effect of exchange rate changes on cash and cash equivalents | ||||||
- | - | 121 | ||||
CASH, CASH EQUIVALENTS AND RESTRICTED CASH: | ||||||
NET INCREASE IN CASH AND CASH EQUIVALENTS | ||||||
- | - | 7,116 | ||||
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||||||
Cash paid during the year for interest | ||||||
12 | 11 | 9 | ||||
SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES: | ||||||
Issuance of common stock to Juvenescence (Note 4) | ||||||
56 | - | - | ||||
Issuance of warrants to Juvenescence (Note 4) | ||||||
236 | - | - | ||||
Issuance of common stock for acquired in-process research and development | ||||||
- | 240 | - | ||||
Settlement of related party payable due to BioTime by LifeMap Sciences and LifeMap Solutions in exchange for common stock, certain assets, and transfer of LifeMap Solutions to BioTime, including proportional equity transfer from noncontrolling interest (see Notes 1 and 4) | ||||||
- | - | 13,223 | ||||
Cancellation of related party payable to BioTime by ReCyte Therapeutics | ||||||
- | - | 11,177 | ||||